From Wikipedia, the free encyclopedia
  (Redirected from BMS-945429)
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Humanized
Target IL6
Clinical data
Routes of
ATC code none
Legal status
Legal status
  • investigational
CAS Number 1236278-28-6
ChemSpider none
Chemical and physical data
Formula C6426H9972N1724O2032S42
Molar mass 145.2 kg/mol

Clazakizumab (formerly ALD518 and BMS-945429)[1] is an aglycosylated, humanized monoclonal antibody against interleukin-6.[2] It is an investigational drug for cancer and rheumatoid arthritis due to its anti-inflammatory properties.

The relatively long half-life of about 30 days should allow less frequent and subcutaneous injections.[3]

It is made using yeast cells rather than the standard Chinese hamster ovary cells.[3]

Clinical trials[edit]


A phase I clinical trial showed ALD518 was well tolerated and could reverse fatigue in cancer patients.[4]

A phase II trial for advanced cancer is due to end in Oct 2009.[5] Results due June 2010.[6] Results from 124 non-small cell lung cancer (NSCLC) patients were favourable (e.g. 1/10 the weight loss).[2]

It may be trialed in a dual therapy with Tarceva owing to a likely synergy.[7]

Rheumatoid arthritis[edit]

The Phase IIa trial for rheumatoid arthritis[8] has completed with promising results leading to a licensing deal allowing phase III trials.[9] The results are to be presented in June 2010 at the European League Against Rheumatism (EULAR) meeting in Rome.[10] [11] Results showed that ALD518 in addition to MTX performs markedly better than MTX + placebo with a maximum ACR score, (ACR70, i.e. >70% of joints improved), after 16 weeks .[12]

2011: A phase 2 trial reported good results in patients not responsive to methotrexate (MTX).[13]

Oct 2013 : A phase 2B clinical trial has met its primary endpoint (ACR20 response at 12 weeks).[1] Adalimumab with MTX was included as a comparison in the trial.[1]

2014 : A dose ranging phase 2B trial was running.[14]

Crohn's disease[edit]

A phase II trial for Crohn's disease initially due to run until 2015.[15] has been prematurely discontinued after having recruited 71 patients out of 288.[16]


Clazakizumab was developed by Alder Biopharmaceuticals and licensed to Vitaeris, Inc. for worldwide marketing.[17]

See also[edit]


  1. ^ a b c Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology
  2. ^ a b "Phase 2a study of ALD518 for treatment of non small cell lung cancer (NSCLC) symptoms". June 2010. 
  3. ^ a b
  4. ^ "A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer.". 2009. 
  5. ^ Phase II: "Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia"
  6. ^
  7. ^ Inflaming resistance to Tarceva. 2010
  8. ^ Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis (ALD518-003)
  9. ^ "Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic". 10 Nov 2009. 
  10. ^ March 2010
  11. ^ "New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism". June 2010. 
  12. ^ "EULAR 2010 Do not miss." (PDF). 2010. 
  13. ^ "A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate". 2012. doi:10.1136/annrheumdis-2011-200704. 
  14. ^ Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
  15. ^ "Alder Gets $3.5M Milestone as Bristol-Myers Starts Crohn's Study". 27 Aug 2012. 
  16. ^
  17. ^

Further reading[edit]